OpenURL Connection Search

Select item for more details and to access through your institution.

P4‐708: CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER'S PATIENTS TREATED WITH CT1812.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1603, doi. 10.1016/j.jalz.2019.09.072
By:
- Schneider, Lon S.;
- Caggiano, Anthony O.;
- Grundman, Michael;
- DeKosky, Steve;
- Morgan, Roger;
- Mozzoni, Kelsie;
- Izzo, Nicholas J.;
- Safferstein, Hank;
- Catalano, Susan
Publication type:
Article
A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1570, doi. 10.1016/j.jalz.2017.07.730
By:
- Catalano, Susan;
- Grundman, Michael;
- Schneider, Lon S.;
- DeKosky, Steven;
- Morgan, Roger;
- Guttendorf, Robert;
- Higgin, Michelle;
- Pribyl, Julie;
- Mozzoni, Kelsie;
- Izzo, Nicholas J.;
- Safferstein, Hank
Publication type:
Article
A TWO-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF CT1812 IN HEALTHY VOLUNTEERS.
Published in:
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1183, doi. 10.1016/j.jalz.2016.07.127
By:
- Catalano, Susan;
- Grundman, Michael;
- Schneider, Lon S.;
- DeKosky, Steven;
- Morgan, Roger;
- Higgin, Michelle;
- Pribyl, Julie;
- Mozzoni, Kelsie;
- Izzo, Nicholas J.;
- Safferstein, Hank;
- Lickliter, Jason
Publication type:
Article
Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity.
Published in:
PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0111899
By:
- Izzo, Nicholas J.;
- Xu, Jinbin;
- Zeng, Chenbo;
- Kirk, Molly J.;
- Mozzoni, Kelsie;
- Silky, Colleen;
- Rehak, Courtney;
- Yurko, Raymond;
- Look, Gary;
- Rishton, Gilbert;
- Safferstein, Hank;
- Cruchaga, Carlos;
- Goate, Alison;
- Cahill, Michael A.;
- Arancio, Ottavio;
- Mach, Robert H.;
- Craven, Rolf;
- Head, Elizabeth;
- IIILeVine, Harry;
- Spires-Jones, Tara L.
Publication type:
Article
Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits.
Published in:
PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0111898
By:
- Izzo, Nicholas J.;
- Staniszewski, Agnes;
- To, Lillian;
- Fa, Mauro;
- Teich, Andrew F.;
- Saeed, Faisal;
- Wostein, Harrison;
- IIIWalko, Thomas;
- Vaswani, Anisha;
- Wardius, Meghan;
- Syed, Zanobia;
- Ravenscroft, Jessica;
- Mozzoni, Kelsie;
- Silky, Colleen;
- Rehak, Courtney;
- Yurko, Raymond;
- Finn, Patricia;
- Look, Gary;
- Rishton, Gilbert;
- Safferstein, Hank
Publication type:
Article
Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.
Published in:
Journal of Neurochemistry, 2021, v. 157, n. 4, p. 1316, doi. 10.1111/jnc.15212
By:
- Limegrover, Colleen S.;
- LeVine, Harry;
- Izzo, Nicholas J.;
- Yurko, Raymond;
- Mozzoni, Kelsie;
- Rehak, Courtney;
- Sadlek, Kelsey;
- Safferstein, Hank;
- Catalano, Susan M.
Publication type:
Article
A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
Published in:
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019, v. 5, n. 1, p. 20, doi. 10.1016/j.trci.2018.11.001
By:
- Grundman, Michael;
- Morgan, Roger;
- Lickliter, Jason D.;
- Schneider, Lon S.;
- DeKosky, Steven;
- Izzo, Nicholas J.;
- Guttendorf, Robert;
- Higgin, Michelle;
- Pribyl, Julie;
- Mozzoni, Kelsie;
- Safferstein, Hank;
- Catalano, Susan M.
Publication type:
Article

Found: 7

P4‐708: CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER'S PATIENTS TREATED WITH CT1812.

A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812.

A TWO-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF CT1812 IN HEALTHY VOLUNTEERS.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity.

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits.

Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.

A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.